Higher court rules in Chugai's favor in Baxalta patent row

3 October 2019

The Japanese Intellectual Property High Court has ruled in favor of the Roche (ROG: SIX) majority-owned subsidiary Chugai (TYO: 4519) in relation to allegations that its hemophilia A drug Hemlibra (emicizumab-kxwh) breached another company’s patent.

Baxalta, a firm that was taken over in 2015 by Shire, which itself is now part of Takeda (TYO: 4502), made the allegation in 2016 and it was initially rejected by the Tokyo District Court in March 2018.

This led Baxalta to appeal to the higher court, which announced on Thursday that it too had found in Chugai’s favor, meaning that the appeal is dismissed and court costs should be paid by Baxalta.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK